// STATE LEGISLATION TRACKER

Minnesota HF 1718: Pharmacy Practice Act clarifying changes made for veterinary compounding, licensure modified for wholesale distributors,

⚖️ NEUTRAL for peptide users 👤 LOW user impact 📜 Status: Failed

State: Minnesota
Bill: HF 1718
Filed: 2019-02-25
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

HF1718 was a pharmacy-regulation cleanup bill, not a peptide-access bill. Its main relevance is indirect: it clarified compounding definitions, veterinary emergency compounding, wholesale drug distribution, third-party logistics licensing, and outsourcing-facility oversight.

Key Points

No clear change to patient access to compounded peptides
No apparent change to off-label prescribing or telehealth
Adds licensing rules for drug logistics providers
Clarifies wholesale distribution and direct-to-patient limits
Veterinary compounding changes do not apply to human peptide use

What to Watch For

Note Compounding pharmacies may face clearer state rules, but this is not peptide-specific.

Concern Wholesale and logistics compliance could add some operational burden for suppliers.

✓

Opportunity Clearer 3PL and wholesaler rules may improve drug supply-chain accountability.

Note No obvious impact on NP, naturopathic, telehealth, or prescription-monitoring rules.

Where the Bill Stands

HF1718 itself appears to have stopped in committee during the 2019-2020 session, though similar provisions were later included in a signed special-session bill.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-10-02 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws